|
ALG9 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.39379999763989E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.84380000051365E-07 |
| Normal-vs-Stage2 |
3.615300E-03 |
| Normal-vs-Stage3 |
5.6761000011285E-08 |
| Normal-vs-Stage4 |
1.84769999966861E-07 |
| Stage1-vs-Stage2 |
3.965200E-01 |
| Stage1-vs-Stage3 |
4.150400E-02 |
| Stage1-vs-Stage4 |
4.644500E-02 |
| Stage2-vs-Stage3 |
4.086200E-02 |
| Stage2-vs-Stage4 |
2.293800E-02 |
| Stage3-vs-Stage4 |
7.321000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.76880002153734E-09 |
| Normal-vs-AfricanAmerican |
3.974500E-02 |
| Normal-vs-Asian |
1.218110E-04 |
| Caucasian-vs-AfricanAmerican |
1.460220E-01 |
| Caucasian-vs-Asian |
3.713400E-01 |
| AfricanAmerican-vs-Asian |
4.592200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.03829999545491E-08 |
| Normal-vs-Female |
1.97979999949638E-07 |
| Male-vs-Female |
1.138220E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.09660000002787E-06 |
| Normal-vs-Age(41-60Yrs) |
1.71719999997322E-07 |
| Normal-vs-Age(61-80Yrs) |
2.56789999997231E-06 |
| Normal-vs-Age(81-100Yrs) |
5.017200E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.627200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.089400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.705600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.664400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.150400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.315600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.036890E-03 |
| Classical-VS-Follicular |
8.464400E-01 |
| Classical-VS-Other |
2.057000E-01 |
| Classical-VS-Normal |
3.70950000000425E-05 |
| Tall-VS-Follicular |
5.936100E-03 |
| Tall-VS-Other |
8.693600E-01 |
| Tall-VS-Normal |
1.90229999530445E-08 |
| Follicular-VS-Other |
3.072600E-01 |
| Follicular-VS-Normal |
6.364700E-04 |
| Other-VS-Normal |
8.558100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.85159999999129E-06 |
| Normal-vs-N1 |
1.06939999966471E-07 |
| N0-vs-N1 |
6.790000E-02 |
|
|
